On January 16, 2025, Yoshinori Ikeura, PhD, Board Director, Co-CEO and CTO, delivered a presentation at the 43rd Annual J.P.Morgan Healthcare Conference.
As one of the world’s largest healthcare investment events, this conference brings together industry leaders and investors to discuss the latest trends, strategies, and initiatives.
For the third consecutive year since 2023, our company has presented as an emerging company from the Asia-Pacific region. This year, in addition to highlighting the business milestones achieved last year, we introduced the market environment surrounding our business, our strengths, key differentiators from competitors, and our strategic initiatives for further growth.
The conference provided us with valuable feedback directly from leaders driving the healthcare industry, reinforcing our confidence in the direction of our business growth.

Comment from Yoshinori Ikeura:
“In this presentation, we articulated Axcelead’s global growth, driven by two core business pillars: the Drug Discovery Business and the mRNA CDMO Business.
In the Drug Discovery Business, we highlighted the establishment of a joint venture with Teijin to enhance our capabilities and capacity, as well as the securing of high-value drug discovery support agreements with leading global pharmaceutical companies, resulting in a higher overseas sales ratio.
In the mRNA CDMO Business, we shared that we have established the first GMP-compliant drug substance manufacturing facility in the Asia-Pacific region and successfully delivered drug substances for next-generation mRNA vaccines.
Moving forward, we will continue to advance our unique healthcare platform to drive further growth in the expanding global CRO and CDMO markets. Through these efforts, we remain committed to a healthy future for people worldwide.”

Click here for presentation materials
Viewing deadline: End of March, 2025